ERBB2 and breast cancer: Moreover, a single arm open label pilot trial is ongoing to assess the combination of dapagliflozin, a sodium/glucose cotransporter-2 (SGLT-2)-inhibitor used to treat diabetes mellitus, with alpelisib + fulvestrant in patients with HR+/HER2− metastatic BC.